Sarepta Therapeutics, Inc. (0L35.L)
USD 63.27
(1.4%)
USD 63.27
(1.4%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -439.19 Million USD | 43.44% |
| 2022 | -582.11 Million USD | -14.9% |
| 2021 | -306.08 Million USD | 22.14% |
| 2020 | -453.37 Million USD | -12.75% |
| 2019 | -652.66 Million USD | -36.95% |
| 2018 | -316.65 Million USD | -43.58% |
| 2017 | -34.75 Million USD | 10.5% |
| 2016 | -261.11 Million USD | -21.14% |
| 2015 | -214.78 Million USD | -68.07% |
| 2014 | -129.97 Million USD | -91.94% |
| 2013 | -88.41 Million USD | -207.05% |
| 2012 | -27.59 Million USD | 192.47% |
| 2011 | -34.62 Million USD | -765.22% |
| 2010 | -19.47 Million USD | -61.64% |
| 2009 | -14.12 Million USD | 47.09% |
| 2008 | -22.48 Million USD | 74.15% |
| 2007 | -25.15 Million USD | -16.69% |
| 2006 | -28.98 Million USD | -99.07% |
| 2005 | -14.67 Million USD | 32.98% |
| 2004 | -22.88 Million USD | -9.46% |
| 2003 | -17.38 Million USD | -8.32% |
| 2002 | -24 Million USD | -740.68% |
| 2001 | -14.84 Million USD | 76.36% |
| 2000 | -9.82 Million USD | -24.36% |
| 1999 | -8 Million USD | -168.7% |
| 1998 | -7.6 Million USD | 402.63% |
| 1997 | -3.4 Million USD | -100.0% |
| 1996 | -1.7 Million USD | 9.52% |
| 1995 | -2.1 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 64.45 Million USD | -4.15% |
| 2024 Q2 | 12.03 Million USD | -79.37% |
| 2023 Q2 | -101.36 Million USD | 5.92% |
| 2023 Q4 | -28.46 Million USD | -327.99% |
| 2023 Q3 | 12.48 Million USD | 112.31% |
| 2023 FY | - USD | 43.44% |
| 2023 Q1 | -107.75 Million USD | -32.23% |
| 2022 Q3 | -112.23 Million USD | 44.49% |
| 2022 FY | - USD | -14.9% |
| 2022 Q4 | -81.49 Million USD | 27.4% |
| 2022 Q1 | -77.63 Million USD | 18.88% |
| 2022 Q2 | -202.17 Million USD | -160.43% |
| 2021 Q4 | -95.69 Million USD | -296.6% |
| 2021 Q1 | -132.81 Million USD | 18.25% |
| 2021 Q2 | -159.48 Million USD | -20.08% |
| 2021 FY | - USD | 22.14% |
| 2021 Q3 | -24.12 Million USD | 84.87% |
| 2020 Q3 | -130.89 Million USD | -0.22% |
| 2020 FY | - USD | -12.75% |
| 2020 Q1 | -105.3 Million USD | 49.47% |
| 2020 Q2 | -130.61 Million USD | -24.04% |
| 2020 Q4 | -162.46 Million USD | -24.12% |
| 2019 Q3 | -110.3 Million USD | -25.53% |
| 2019 Q1 | -62.85 Million USD | 54.83% |
| 2019 Q2 | -87.86 Million USD | -39.8% |
| 2019 Q4 | -208.39 Million USD | -88.93% |
| 2019 FY | - USD | -36.95% |
| 2018 Q1 | -25.33 Million USD | -10.5% |
| 2018 Q4 | -139.14 Million USD | -99.11% |
| 2018 Q3 | -69.88 Million USD | 30.01% |
| 2018 FY | - USD | -43.58% |
| 2018 Q2 | -99.84 Million USD | -294.07% |
| 2017 Q4 | -22.93 Million USD | -479.09% |
| 2017 FY | - USD | 10.5% |
| 2017 Q3 | 6.04 Million USD | 110.49% |
| 2017 Q2 | -57.66 Million USD | 64.89% |
| 2017 Q1 | -164.24 Million USD | -85.81% |
| 2016 Q4 | -88.39 Million USD | -56.36% |
| 2016 Q2 | -62.1 Million USD | -6.51% |
| 2016 FY | - USD | -21.14% |
| 2016 Q1 | -58.3 Million USD | 9.54% |
| 2016 Q3 | -56.53 Million USD | 8.96% |
| 2015 FY | - USD | -68.07% |
| 2015 Q4 | -64.45 Million USD | -27.75% |
| 2015 Q3 | -50.45 Million USD | -23.61% |
| 2015 Q2 | -40.81 Million USD | 34.02% |
| 2015 Q1 | -61.86 Million USD | -38.33% |
| 2014 FY | - USD | -91.94% |
| 2014 Q2 | -25.52 Million USD | -19.58% |
| 2014 Q3 | -36.88 Million USD | -44.48% |
| 2014 Q4 | -44.72 Million USD | -21.26% |
| 2014 Q1 | -21.34 Million USD | 62.44% |
| 2013 Q2 | -14.88 Million USD | -224.62% |
| 2013 Q3 | -7.48 Million USD | 49.7% |
| 2013 Q4 | -56.83 Million USD | -659.19% |
| 2013 Q1 | 11.94 Million USD | -71.47% |
| 2013 FY | - USD | -207.05% |
| 2012 FY | - USD | 192.47% |
| 2012 Q1 | 4.4 Million USD | 127.69% |
| 2012 Q2 | -18.68 Million USD | -524.13% |
| 2012 Q3 | 35.81 Million USD | 291.68% |
| 2012 Q4 | 41.85 Million USD | 16.87% |
| 2011 Q3 | -18.32 Million USD | 14.29% |
| 2011 Q1 | -12.8 Million USD | -374.61% |
| 2011 Q4 | -15.9 Million USD | 13.19% |
| 2011 Q2 | -21.37 Million USD | -66.95% |
| 2011 FY | - USD | -765.22% |
| 2010 Q1 | -14.49 Million USD | -361.54% |
| 2010 FY | - USD | -61.64% |
| 2010 Q2 | 1.72 Million USD | 111.89% |
| 2010 Q3 | 136 Thousand USD | -92.11% |
| 2010 Q4 | 4.66 Million USD | 3328.68% |
| 2009 FY | - USD | 47.09% |
| 2009 Q3 | 2.11 Million USD | -78.56% |
| 2009 Q4 | 5.54 Million USD | 162.08% |
| 2009 Q2 | 9.86 Million USD | 269.47% |
| 2009 Q1 | -5.82 Million USD | -39.05% |
| 2008 FY | - USD | 74.15% |
| 2008 Q3 | -5.42 Million USD | 28.43% |
| 2008 Q2 | -7.57 Million USD | -198.39% |
| 2008 Q1 | 7.7 Million USD | 217.28% |
| 2008 Q4 | -4.18 Million USD | 22.82% |
| 2007 Q2 | -8.35 Million USD | 13.06% |
| 2007 FY | - USD | -16.69% |
| 2007 Q4 | -6.56 Million USD | 29.17% |
| 2007 Q3 | -9.27 Million USD | -11.01% |
| 2007 Q1 | -9.6 Million USD | -16.54% |
| 2006 FY | - USD | -99.07% |
| 2006 Q4 | -8.24 Million USD | -22.11% |
| 2006 Q3 | -6.75 Million USD | 2.26% |
| 2006 Q2 | -6.9 Million USD | 23.21% |
| 2006 Q1 | -8.99 Million USD | -105.58% |
| 2005 Q2 | -4.65 Million USD | 7.99% |
| 2005 Q1 | -5.06 Million USD | -14.55% |
| 2005 Q4 | -4.37 Million USD | -206.86% |
| 2005 Q3 | -1.42 Million USD | 69.38% |
| 2005 FY | - USD | 32.98% |
| 2004 FY | - USD | -9.46% |
| 2004 Q3 | -5.12 Million USD | 29.16% |
| 2004 Q4 | -4.41 Million USD | 13.75% |
| 2004 Q2 | -7.23 Million USD | 1.27% |
| 2004 Q1 | -7.32 Million USD | -9.28% |
| 2003 Q1 | -3.14 Million USD | 16.56% |
| 2003 Q4 | -6.7 Million USD | -54.79% |
| 2003 FY | - USD | -8.32% |
| 2003 Q2 | -3.2 Million USD | -1.92% |
| 2003 Q3 | -4.32 Million USD | -34.94% |
| 2002 Q4 | -3.77 Million USD | -16.74% |
| 2002 Q1 | -7.62 Million USD | -69.73% |
| 2002 Q2 | -7.58 Million USD | 35.85% |
| 2002 Q3 | -5.02 Million USD | 33.97% |
| 2002 FY | - USD | -740.68% |
| 2001 Q4 | -4.49 Million USD | -148.36% |
| 2001 FY | - USD | 76.36% |
| 2001 Q3 | -3.22 Million USD | 352.92% |
| 2001 Q2 | -3.67 Million USD | -6.59% |
| 2001 Q1 | -3.44 Million USD | -5.36% |
| 2000 Q3 | -2.5 Million USD | 13.03% |
| 2000 Q2 | -2.87 Million USD | -146.58% |
| 2000 FY | - USD | -24.36% |
| 2000 Q1 | -1.16 Million USD | 49.22% |
| 2000 Q4 | -3.27 Million USD | -30.64% |
| 1999 Q1 | -1.5 Million USD | 42.31% |
| 1999 FY | - USD | -168.7% |
| 1999 Q3 | -2.09 Million USD | -5.26% |
| 1999 Q4 | -2.3 Million USD | -15.0% |
| 1999 Q2 | -1.9 Million USD | -26.67% |
| 1998 Q2 | -1.7 Million USD | -6.25% |
| 1998 FY | - USD | 402.63% |
| 1998 Q4 | -2.6 Million USD | -114.69% |
| 1998 Q3 | -1.7 Million USD | 1141.18% |
| 1998 Q1 | -1.4 Million USD | -77.78% |
| 1997 Q1 | -500 Thousand USD | -40.0% |
| 1997 Q2 | -1 Million USD | -57.14% |
| 1997 Q3 | -1.1 Million USD | 0.0% |
| 1997 FY | - USD | -100.0% |
| 1997 Q4 | -800 Thousand USD | 18.18% |
| 1996 Q3 | -440 Thousand USD | 0.0% |
| 1996 Q1 | 50 Thousand USD | 0.0% |
| 1996 Q2 | -440 Thousand USD | -980.0% |
| 1996 Q4 | -500 Thousand USD | -13.64% |
| 1996 FY | - USD | 9.52% |
| 1995 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Editas Medicine, Inc. | -163.11 Million USD | -169.252% |
| Dynavax Technologies Corporation | 9.66 Million USD | 4643.72% |
| Cara Therapeutics, Inc. | -117.65 Million USD | -273.307% |
| Walgreens Boots Alliance, Inc. | -11.27 Billion USD | 96.106% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | 546.964% |
| Perrigo Company plc | 646.2 Million USD | 167.966% |
| Atara Biotherapeutics, Inc. | -265.99 Million USD | -65.113% |
| Illumina, Inc. | -608 Million USD | 27.764% |
| Thermo Fisher Scientific Inc. | 10.8 Billion USD | 104.067% |
| Nektar Therapeutics | -243.1 Million USD | -80.66% |
| Iovance Biotherapeutics, Inc. | -449.01 Million USD | 2.186% |
| IQVIA Holdings Inc. | 3.25 Billion USD | 113.489% |
| Heron Therapeutics, Inc. | -103.79 Million USD | -323.15% |
| Unity Biotechnology, Inc. | -37.28 Million USD | -1078.006% |
| BioMarin Pharmaceutical Inc. | 310.28 Million USD | 241.546% |
| Waters Corporation | 1.02 Billion USD | 142.964% |
| Biogen Inc. | 2.37 Billion USD | 118.477% |
| Sangamo Therapeutics, Inc. | -87.42 Million USD | -402.357% |
| Adicet Bio, Inc. | -136.53 Million USD | -221.673% |
| Agilent Technologies, Inc. | 1.67 Billion USD | 126.189% |
| Homology Medicines, Inc. | -47.75 Million USD | -819.667% |
| Geron Corporation | -174.78 Million USD | -151.282% |
| Alnylam Pharmaceuticals, Inc. | -228.12 Million USD | -92.528% |
| Amicus Therapeutics, Inc. | -92.07 Million USD | -376.977% |
| Myriad Genetics, Inc. | -67.8 Million USD | -547.782% |
| Evolus, Inc. | -41.81 Million USD | -950.457% |
| Anavex Life Sciences Corp. | -55.75 Million USD | -687.711% |
| bluebird bio, Inc. | -167.16 Million USD | -162.738% |
| Intellia Therapeutics, Inc. | -506.31 Million USD | 13.256% |
| Zoetis Inc. | 3.68 Billion USD | 111.918% |
| Abeona Therapeutics Inc. | -50.57 Million USD | -768.457% |
| Aclaris Therapeutics, Inc. | -87.98 Million USD | -399.171% |
| Mettler-Toledo International Inc. | 1.16 Billion USD | 137.73% |
| Vertex Pharmaceuticals Incorporated | 4.6 Billion USD | 109.537% |
| uniQure N.V. | -253.1 Million USD | -73.527% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | -1117.216% |
| Ionis Pharmaceuticals, Inc. | -230.01 Million USD | -90.946% |
| Verastem, Inc. | -83.16 Million USD | -428.096% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | -192.587% |
| FibroGen, Inc. | -261.4 Million USD | -68.014% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.43 Million USD | -888.363% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 205.551% |
| Regeneron Pharmaceuticals, Inc. | 4.65 Billion USD | 109.437% |
| OPKO Health, Inc. | -65.51 Million USD | -570.364% |
| Viking Therapeutics, Inc. | -100.82 Million USD | -335.594% |
| Exelixis, Inc. | 196.6 Million USD | 323.393% |
| Halozyme Therapeutics, Inc. | 451.94 Million USD | 197.179% |
| Axsome Therapeutics, Inc. | -224.99 Million USD | -95.206% |
| Imunon, Inc. | -20.78 Million USD | -2013.32% |
| Blueprint Medicines Corporation | -474.61 Million USD | 7.462% |
| Insmed Incorporated | -654.73 Million USD | 32.92% |
| Agios Pharmaceuticals, Inc. | -345.46 Million USD | -27.132% |
| Corcept Therapeutics Incorporated | 108.32 Million USD | 505.447% |
| TG Therapeutics, Inc. | 26.1 Million USD | 1782.743% |
| Incyte Corporation | 919.42 Million USD | 147.768% |
| Emergent BioSolutions Inc. | -505.29 Million USD | 13.082% |